You are here



authors Anzalone and La Rocca
Jan 2014   When someone thinks to the potential of regenerative medicine, the main idea is that of immature cells which may transdifferentiate towards a mature cell type, which may be used to repopulate a target organ cells, and thereby treat human diseases. This concept drives a lot of research undertaken worldwide. Wharton's jelly mesenchymal stem cells (WJ-MSC) are not an exception to this rule: They are derived from the tissue constituting the bulk of the umbilical cord (1). Applications of these cells, often supported by data from several in vivo models, range from the nervous system to the liver, pancreas, heart and other organs in the body (2-4).
Jan 2014   Recently, two exciting studies in China were published that highlight the co-transplantation of human umbilical cord mesenchymal stem cells (UC-MSC) and human umbilical cord blood hematopoietic stem cells (CB-HSC) into human patients. These papers provide some of the first human data to support a scientific hypothesis that was first suggested at the 7th International Cord Blood Society (ICBS) Congress in 2004 (1).
map of MSC trials by country January 2014
Jan 2014   Most scientists think of mesenchymal stromal cells (MSC, or mesenchymal stem cells) as being associated with bone marrow or adipose tissue. However, new explorations of MSC derived from umbilical cord tissue (UC-MSC) promises abundance and great therapeutic value of these cells.